173 related articles for article (PubMed ID: 7923135)
1. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
2. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Ashour OM; Naguib FN; Khalifa MM; Abdel-Raheem MH; Panzica RP; el Kouni MH
Cancer Res; 1995 Mar; 55(5):1092-8. PubMed ID: 7866994
[TBL] [Abstract][Full Text] [Related]
4. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.
Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H
Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.
Brunetti I; Falcone A; Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 1990 Jul; 50(13):4026-31. PubMed ID: 2354452
[TBL] [Abstract][Full Text] [Related]
6. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
8. High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1982 Oct; 42(10):3964-70. PubMed ID: 7104997
[TBL] [Abstract][Full Text] [Related]
9. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Ciccolini J; Peillard L; Evrard A; Cuq P; Aubert C; Pelegrin A; Formento P; Milano G; Catalin J
Clin Cancer Res; 2000 Apr; 6(4):1529-35. PubMed ID: 10778986
[TBL] [Abstract][Full Text] [Related]
11. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
Blumenthal RD; Sharkey RM; Natale AM; Kashi R; Wong G; Goldenberg DM
Cancer Res; 1994 Jan; 54(1):142-51. PubMed ID: 8261435
[TBL] [Abstract][Full Text] [Related]
12. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
15. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
16. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate.
Ho DH; Townsend L; Luna MA; Bodey GP
Anticancer Res; 1986; 6(4):781-4. PubMed ID: 3752956
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy.
Daher GC; Naguib FN; el Kouni MH; Zhang RW; Soong SJ; Diasio RB
Biochem Pharmacol; 1991 Jun; 41(12):1887-93. PubMed ID: 1828154
[TBL] [Abstract][Full Text] [Related]
18. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
Zimmerman RJ; VanWinkle TJ; Mantel N; Frei E; Goldin A
Cancer Res; 1986 Feb; 46(2):694-700. PubMed ID: 3940636
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
Huber BE; Austin EA; Good SS; Knick VC; Tibbels S; Richards CA
Cancer Res; 1993 Oct; 53(19):4619-26. PubMed ID: 8402637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
